INTERNATIONAL PATENT: NALO THERAPEUTICS, INC. FILES APPLICATION FOR "N-(1-((R)-1-ACRYLOYLAZEPAN-3-YL)-7-CHLORO-6-(((R)-TETRAHYDROFURAN-3-YL)OXY)-1H-B ENZO[D]IMIDAZOL-2-YL)-2-METHYLISONICOTINAMIDE (NX-019) FOR USE IN THE TREATMENT OF EGFR MUTANT CANCER"

GENEVA, Aug. 26 -- NALO THERAPEUTICS, INC. (628 Middlefield Rd.Palo Alto, CA 94301) filed a patent application (PCT/US2025/015997) for "N-(1-((R)-1-ACRYLOYLAZEPAN-3-YL)-7-CHLORO-6-(((R)-TETRAHYDROFURAN-3-YL)OXY)-1H-B ENZO[D]IMIDAZOL-2-YL)-2-METHYLISONICOTINAMIDE (NX-019) FOR USE IN THE TREATMENT OF EGFR MUTANT CANCER" on Feb 14, 2025. With publication no. WO/2025/175145, the details related to the patent application was published on Aug 21, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): WILSON, Keith (Nalo Therapeutics, Inc.628 Middlefield Rd.Palo Alto, CA 94301)

Abstract: NX-019 is a po...